4 news items
Processa Pharmaceuticals Announces Results From Phase 1b Trial Of Next Generation Capecitabine For Stage III/IV GI Cancer, Establishing Maximum Tolerated Dose And Recommended Phase 2 Dose Range
PCSA
11 Jun 24
dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD)For all NGC-Cap doses, 5
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
PCSA
11 Jun 24
, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
PCSA
28 Mar 24
discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
PCSA
25 Mar 24
NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response
- Prev
- 1
- Next